journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Pharmacotherapy

journal
https://www.readbyqxmd.com/read/29676942/pharmacotherapy-for-schizophrenia-in-postmenopausal-women
#1
Alexandre González-Rodríguez, Mary V Seeman
Reduced estrogen levels at menopause mean a loss of the neuroprotection that is conferred, from puberty until menopause, on women with schizophrenia. The postmenopausal stage of schizophrenia requires therapeutic attention because women with this diagnosis almost invariably experience increased symptoms and increased side effects at this time. So far, few targeted therapies have been successfully developed. Areas covered: This non-systematic, narrative review is based on the relevant published literature indexed in PubMed...
April 20, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29676935/current-and-emerging-two-drug-approaches-for-hiv-1-therapy-in-art-na%C3%A3-ve-and-art-experienced-virologically-suppressed-patients
#2
Barbara Rossetti, Francesca Montagnani, Andrea De Luca
Current guidelines recommend a 2-drug antiretroviral regimen as an alternative to triple antiretroviral therapy (ART) in selected patients to reduce long-term toxicity and costs. Areas covered: This review is intended to provide insight into the efficacy, safety and tolerability of 2-drug versus 3-drug ART in naïve and in treatment-experienced virologically-suppressed patients. Expert opinion: Dual therapy regimens are not feasible in HBV-coinfected individuals and should not be applied during pregnancy. Positive data on 2-drug ART in drug naïve patients are still limited, while, in virologically-suppressed individuals, several regimens have shown non-inferiority as compared to 3-drug regimens...
April 20, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29672177/extended-release-drug-formulations-for-the-treatment-of-epilepsy
#3
Christian Brandt, Theodor W May
Extended-release (ER) preparations are either available or have been tested for several antiepileptic drugs (AEDs). Indeed, they may be helpful in improving efficacy, tolerability, adherence, compared to the corresponding immediate release (IR) preparations available. The use of ER preparations has been advocated in women of childbearing age and is - depending on the drug - especially helpful in patients who are treated in combination with enzyme inducing AEDs as well as in children. Areas covered: Clinical and pharmacokinetic studies on ER formulations of AEDs were identified by a PubMed literature research...
April 19, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29672168/rucaparib-a-new-treatment-option-for-ovarian-cancer
#4
Ilaria Sabatucci, Giuseppa Maltese, Stefano Lepori, Elisa Tripodi, Giorgio Bogani, Domenica Lorusso
Approximately 50% of high-grade serous ovarian cancers present a deficiency in the pathways involved in homologous recombination (HR). PARP inhibitors prevent single-strand DNA damage repair and determine a progression of the defect towards double-strand breaks, which results in a process known as 'synthetic lethality'. Areas covered: In this review, the authors discuss the efficacy and toxicity of rucaparib either as a single agent or as a maintenance treatment for ovarian cancer. This includes the NGS Foundation Medicine evaluation of the role of this drug in the treatment algorithm of ovarian cancer...
April 19, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29667439/what-is-the-impact-of-the-2017-cochrane-systematic-review-and-meta-analysis-that-evaluated-the-use-of-pcsk9-inhibitors-for-lowering-cardiovascular-disease-and-mortality
#5
Mohamed A Jalloh, Eric J Ip, Shadi Doroudgar
In 2017, Schmidt et al. conducted a Cochrane systematic review and meta-analysis to evaluate the effect of using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce low-density-lipoprotein- cholesterol (LDL-C) and cardiovascular disease (CVD). The Cochrane review was a systematic review and meta-analysis of 20 randomized, double-blinded trials that compared the use of PCSK9 inhibitors with statins/ezetimibe, ezetimibe, or placebo for a treatment duration of at least 24 weeks. The use of PCSK9 inhibitors lowered the risk for CVD (OR 0...
April 18, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29658795/an-update-and-systematic-review-on-drug-therapies-for-the-treatment-of-refractory-chronic-cough
#6
Nicole M Ryan, Anne E Vertigan, Surinder S Birring
Chronic Cough (CC) is common and often associated with significant comorbidity and decreased quality of life. In up to 50% of cases, the cough is refractory despite extensive investigation and treatment trials. It is likely that the key abnormality in refractory CC is dysfunctional, hypersensitive sensory nerves, similar to conditions such as laryngeal hypersensitivity and neuropathic pain. Areas covered: The aim of this systematic review is to assess drug therapies for refractory CC. The authors review the current management of CC and provide discussion of the similarities between neuropathic pain and refractory CC...
April 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29648925/intravenous-carbamazepine-for-the-treatment-of-epilepsy
#7
Francesco Brigo, Antonio Leo, Emilio Russo, Pasquale Striano, Vincenzo Belcastro
Recently, an intravenous formulation of carbamazepine (CBZ) (sulphobutylether-7-beta-cyclodextrine carbamazepine, SBECD CBZ) has been developed and approved by the U.S. Food and Drug Administration. It is indicated as a short-term replacement therapy for oral CBZ formulations, when oral administration is temporarily not feasible and in adults with focal seizures with complex symptomatology as well as generalized tonic-clonic seizures and mixed seizure patterns. Areas covered: This review focuses on the drug development, pharmacokinetics and pharmacodynamics of intravenous CBZ and provides a comprehensive overview of the studies assessing its clinical efficacy, tolerability and safety in adults with epilepsy...
April 12, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29638149/masitinib-in-treatment-of-pancreatic-cancer
#8
Anem Waheed, Sneha Purvey, Muhammad Wasif Saif
Pancreatic cancer continues to have high mortality despite the development of many chemotherapeutic agents. The 5-year relative survival for stage IV patients is less than 3%. This urgent unmet need warrants the development of novel and active therapeutic agents, which focus both on targeting cancer cells and modifying the microenvironment of cancer cells. Areas covered: In this article, the authors review the development of masitinib, a novel tyrosine kinase inhibitor of numerous targets, including c-Kit, PDGFR and FGFR...
April 11, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29637798/levonorgestrel-releasing-intra-uterine-systems-as-female-contraceptives
#9
Giovanni Grandi, Antonino Farulla, Filomena Giulia Sileo, Fabio Facchinetti
The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. Areas covered: The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. Expert opinion: The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19...
April 11, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29634360/sofosbuvir-velpatasvir-voxilaprevir-for-the-treatment-of-hepatitis-c-infection
#10
Theodore J Cory, Ying Mu, Yuqing Gong, Sunitha Kodidela, Santosh Kumar
Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized. Therapy has transformed over the last several years with the approval of second generation direct acting antivirals, and currently utilized medications for the treatment of hepatitis C are significantly more efficacious with better safety profiles than previously approved treatments. Treatment for individuals who have failed therapy on direct acting antivirals has, until recently, been complex and difficult to treat, but the approval of sofosbuvir/velpatasvir/voxilaprevir represents a new therapeutic option for these individuals...
April 10, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29611444/combination-oral-antithrombotic-therapy-for-the-treatment-of-myocardial-infarction-recent-developments
#11
Udaya S Tantry, Eliano P Navarese, Aung Myat, Rahul Chaudhary, Paul A Gurbel
There have been significant new developments in the treatment of patients with myocardial infarction with respect to oral antithrombotic agents over the past decade. Recent studies have explored the potential utility of targeting the dual pathway inhibition of platelet function with single or dual antiplatelet agents and the thrombin pathway with direct thrombin inhibitors or factor Xa inhibitors. Areas covered: In this review, the authors focus on the recent developments of oral antithrombotic agents including antiplatelet and antithrombin agents...
April 3, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29600880/pharmacotherapeutic-strategies-for-treating-hypertension-in-patients-with-obesity
#12
Revathy Carnagarin, Vance Matthews, Cynthia Gregory, Markus P Schlaich
Hypertension and obesity are important health challenges that independently increase cardiovascular morbidity and mortality. There is a lack of randomized controlled trials to clearly inform on preferred drug choices to be adopted in clinical practice for the treatment of obesity-related hypertension (OHT). Adequate differentiation of drug classes for preferential use in obesity or the metabolic syndrome aimed at avoiding adverse effects on body weight and the metabolic profile is neglected in this population, at least in part due to the lack of specific pharmacologic recommendations in hypertension guidelines...
March 30, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29591723/improvement-in-the-proinsulin-c-peptide-ratio-during-treatment-with-ipragliflozin-in-japanese-patients-with-type-2-diabetes-mellitus
#13
Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Tatsuya Atsumi, Hideaki Miyoshi
No abstract text is available yet for this article.
March 29, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29589486/advances-in-chemical-pharmacotherapy-for-the-treatment-of-pediatric-immune-thrombocytopenia
#14
Thomas Kühne
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder of heterogeneous pathophysiological mechanisms. Treatment endpoints include elevation of platelets and reduction of bleeding risk, elevation of quality of life, reduction of concomitant therapies and prevention from bleeding. Persistent and chronic ITP is more common in adults but occurs in children. Standard therapies include corticosteroids and immunoglobulins, both associated with side effects. There are new treatments, such as thrombopoietin-receptor agonists and promising investigational drugs...
March 28, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29578856/drug-treatment-of-hypertension-in-older-patients-with-diabetes-mellitus
#15
Srikanth Yandrapalli, Suman Pal, Christopher Nabors, Wilbert S Aronow
Hypertension is more prevalent in the elderly (age>65 years) diabetic population than in the general population and shows an increasing prevalence with advancing age. Both diabetes mellitus (DM) and hypertension are independent risk factors for cardiovascular (CV) related morbidity and mortality. Optimal BP targets were not identified in elderly patients with DM and hypertension. Areas covered: In this review article, the authors briefly discuss the pathophysiology of hypertension in elderly diabetics, present evidence with various antihypertensive drug classes supporting the treatment of hypertension to reduce CV events in older diabetics, and then discuss the optimal target BP goals in these patients...
March 26, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29578822/pharmacotherapy-for-chronic-non-specific-low-back-pain-current-and-future-options
#16
Bart W Koes, Daan Backes, Patrick J E Bindels
Low back pain is associated with a large burden-of-illness. It is responsible for the most years lived with disability as compared with any other medical condition. A comprehensive overview of the evidence on pharmacological treatment options for chronic low back pain is lacking. This review evaluates the evidence for the benefits and risks of currently available pharmacological treatments for chronic low back pain. Areas covered: The authors focus on the recent (Cochrane) systematic reviews and meta-analyses of randomized clinical trials covering paracetamol (acetaminophen), NSAIDs, muscle relaxants, antidepressants, anticonvulsants, opioids, and other (new) drugs...
March 26, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29565192/pharmacotherapeutic-approaches-for-treating-psoriasis-in-difficult-to-treat-areas
#17
Dario Kivelevitch, Jillian Frieder, Ian Watson, So Yeon Paek, M Alan Menter
Despite great therapeutic advancements in psoriasis, four notable difficult-to-treat areas including the scalp, nails, intertriginous (including genitals), and palmoplantar regions, pose a challenge to both physicians and patients. Localized disease of these specific body regions inflicts a significant burden on patients' quality of life and requires an adequate selection of treatments. Areas covered: This manuscript discusses appropriate therapies and important treatment considerations for these difficult-to-treat areas based on the available clinical data from the literature...
March 22, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29565182/are-traditional-approaches-diminishing-the-bipolar-drug-pipeline
#18
Charles Bowden, Melissa Martinez
No abstract text is available yet for this article.
March 22, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29557204/next-generation-fixed-dose-combination-pharmacotherapies-for-treating-hiv
#19
Margaret R Caplan, Eric S Daar, Katya C Corado
Treatment options for patients with HIV-1 infection have grown over the past two decades to include multiple fixed-dose combination pharmacotherapies that have greatly simplified administration of antiretroviral therapy (ART) for both patients and providers. Effective virologic control can often be achieved with once-daily use of a single-tablet regimen. Over the past three years, ART drug development has focused on the next generation of fixed-dose combinations for initial and maintenance therapy with improved efficacy, safety and tolerability...
March 20, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29542350/pharmacotherapy-of-retinal-disease-with-visual-cycle-modulators
#20
Rehan M Hussain, Ninel Z Gregori, Thomas A Ciulla, Byron L Lam
Pharmacotherapy with visual cycle modulators (VCMs) is under investigation for retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related macular degeneration (AMD), all blinding diseases that lack effective treatment options. Areas covered: The authors review investigational VCMs, including oral retinoids, 9-cis-retinyl-acetate (zuretinol) and 9-cis-β-carotene, which restore 11-cis-retinal levels in RP and LCA caused by LRAT and RPE65 gene mutations, and may improve visual acuity and visual fields...
March 15, 2018: Expert Opinion on Pharmacotherapy
journal
journal
34813
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"